Target intelligence / Profile preview

Pathogenic bacterium in gut microbiota

Molecular classification
Other (heterogeneous group of bacterial species)
01

Overview

“Pathogenic bacterium in gut microbiota” is not a single molecular entity but refers to any bacterial species within the human gastrointestinal tract that has been associated with disease. The term encompasses a diverse set of organisms—including but not limited to Klebsiella pneumoniae, Bacteroides fragilis, certain strains of Escherichia coli (such as EPEC and EHEC), Clostridium difficile, and others—that can cause infections or contribute to inflammatory conditions when present at high abundance or under dysbiotic conditions[1][4][5]. These organisms are classified based on their potential to cause harm rather than shared molecular features. Their presence is context-dependent; some may be harmless commensals under normal circumstances but become pathogenic if host defenses are compromised. Because “pathogenic bacterium in gut microbiota” does not refer to a unique molecule, receptor, enzyme, transporter, or other canonical therapeutic target class—and instead describes an ecological role within the complex community structure—it is not considered an appropriate entry for structured drug-target databases. Instead, each individual pathogen should be listed separately by its scientific name for precise targeting information[1][3]. In summary: This entry is too broad and non-specific for structured therapeutic targeting purposes. It should be replaced with entries corresponding to individual pathogenic bacterial species found within the human gastrointestinal tract.

Other names
Pathogenic bacteria in gut floraHarmful gut bacteriaPotential pathogenic bacteria of the human gut microbiome
02

Mechanism of action

Mechanisms depend on the specific drug and bacterial species; for example, antibiotics inhibit cell wall synthesis or protein synthesis in susceptible pathogens.

03

Biological functions

InfectionImmune modulationDisruption of intestinal barrier functionInflammation induction
04

Disease associations

Infection (gastrointestinal and systemic)Inflammation (e.g., inflammatory bowel disease)Other (metabolic disorders, sepsis, etc.)
05

Safety considerations

Safety concerns relate to broad-spectrum antibiotic use—such as disruption of beneficial microbiota and development of resistance—rather than targeting this group as a whole.

Beyond the preview

Go deeper on Pathogenic bacterium in gut microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic bacterium in gut microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call